Oral immunization of mice with gamma-irradiated Brucella neotomae induces protection against intraperitoneal and intranasal challenge with virulent B. abortus 2308

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Dabral, Neha ^a   Moreno Lafont, Martha ^a,b   Sriranganathan, Nammalwar ^c   Vemulapalli, Ramesh ^a  

^a PURDUE UNIVERSITY   (United States)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUCELLA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; EPITOPE; IMMUNOGLOBULIN CLASS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BRUCELLA; BRUCELLA ABORTUS; BRUCELLA ABORTUS 2308; BRUCELLA ABORTUS RB51; BRUCELLA NEOTOMAE; BRUCELLOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GAMMA IRRADIATION; HUMORAL IMMUNITY; IMMUNIZATION; LIVER; LUNG; MOUSE; NONHUMAN; PRIME BOOST IMMUNIZATION; PROVOCATION TEST; SPLEEN; ANIMAL; BLOOD; CROSS REACTION; DISEASE MODEL; GAMMA RADIATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; RADIATION RESPONSE;

BRUCELLA MELITENSIS BIOVAR ABORTUS; BRUCELLA MELITENSIS BIOVAR NEOTOMAE; MUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BRUCELLA; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; EPITOPES, B-LYMPHOCYTE; FEMALE; GAMMA RAYS; IMMUNIZATION; IMMUNOGLOBULIN ISOTYPES; INJECTIONS, INTRAPERITONEAL; MICE;

EID: 84907266440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107180     Document Type: Article

References (26)

1. Franco MP, Mulder M, Gilman RH, Smits HL (2007) Human brucellosis. Lancet Infect Dis 12: 775-786.
2. Ferreira P, Gama P, Correia J, Nunes L, Pipa J, et al. (2008) Brucella endocarditis- case report and literature review. Rev Port Cardiol 27: 1309-1315.
3. Araya LN, Elzer PH, Rowe GE, Enright FM, Winter AJ (1989) Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol 143: 3330-3337.
4. Murphy EA, Sathiyaseelan J, Parent MA, Zou B, Baldwin CL (2001) Interferongamma is crucial for surviving a Brucella infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103: 511-518.
5. Zhan YF, Liu ZQ, Cheers C (1996) Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms. Infect Immun 64: 2782-2786.
6. Vitry MA, Mambres DH, Trez CD, Akira S, Ryffel B, et al. (2014) Humoral immunity and CD4 + Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis. J. Immunol 192: 3740-3752.
7. Araya LN, Winter AJ (1990) Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum. Infect Immun 58: 254-256.
8. Ficht TA, Kahl-Mcdonagh MM, Arenas-Gamboa AM, Rice-Ficht AC (2009) Brucellosis: the case for live, attenuated vaccines. Vaccine 27: D40-D3.
9. Blasco JM, Diaz R (1993) Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 342: 805.
10. Perkins SD, Smither SJ, Atkins HS (2010) Towards a Brucella vaccine for humans. FEMS Microbiol Rev 34: 379-394.
11. Moustafa D, Garg VK, Jain N, Sriranganathan N, Vemulapalli R (2011) Immunization of mice with gamma-irradiated B. neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis and B. suis challenge. Vaccine 29: 784-794.
12. Sanakkayala N, Sokolovska A, Gulani J, HogenEsch H, Sriranganathan N, et al. (2005) Induction of antigen-specific Th1-type immune responses by gammairradiated recombinant Brucella abortus RB51. Clin Diagn Lab Immunol 12: 1429-1436.
13. Morrison DC, Leive L (1975) Fractions of Lipopolysaccharide from Escherichia coli O111-B4 prepared by two extraction procedures. J Biol Chem 250: 2911-2919.
14. Phillips M, Pugh GW, Deyoe BL (1989) Chemical and protective properties of Brucella lipopolysaccharide obtained by butanol extraction. Am J Vet Res 50: 311-317.
15. Vemulapalli R, Duncan AJ, Boyle SM, Sriranganathan N, Toth TE, et al. (1998) Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51. Infect Immun 66: 5684-5691.
16. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJD, Zajac AJ, et al. (1998) Counting antigen-specific CD8T cells: a reevaluation of bystander activation during viral infection. Immunity 8: 177-187.
17. Schurig GG, Roop RM, Bagchi T, Boyle S, Buhrman D, et al. (1999) Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol 28: 171-188.
18. Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL (2004) Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16 M. Infect Immun 72: 4031-4039.
19. Young EJ (1995) An overview of human brucellosis. Clin Infect Dis 21: 283-289.
20. Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F (2003) Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infect Immun 71: 2326-2330.
21. Clapp B, Skyberg JA, Yang X, Thornburg T, Walters N, et al. (2011) Protective live oral brucellosis vaccines stimulate Th1 and Th17 cell responses. Infect Immun 79: 4165-4174.
22. Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF (2003) Experience with registered mucosal vaccines. Vaccine 21: 678-683.
23. Cloeckaert A, Verger JM, Grayon M, Vizcaino N (1996) Molecular and immunological characterization of the major outer membrane proteins of Brucella. FEMS Microbiol Lett 145: 1-8.
24. Gonzalez D, Grillo MJ, De Miguel MJ, Ali T, Arce-Gorvel V, et al. (2008) Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PloS One 3: e2760.
25. Montaraz JA, Winter AJ (1986) Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice. Infect Immun 53: 245-251.
26. Kahl-McDonagh MM, Ficht TA (2006) Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect Immun 74: 4048-4057.